Mark Fisher, Aaron L. Burshtein, Joshua G. Burshtein, Panagiotis Manolas, Scot B. Glasberg
Original article
Mark Fisher, Aaron L. Burshtein, Joshua G. Burshtein, Panagiotis Manolas, Scot B. Glasberg
More than 100,000 reduction mammaplasties are performed in the United States each year. There is large variance in reported incidence of cancerous/high-risk lesions, ranging from 0.06% to 4.6%. There has been debate whether histological review of breast reduction specimen is necessary.
Official website: Pathology Examination of Breast Reduction Specimens: Dispelling the Myth
Sign in or register for free to read the full article
Share: